IRWD · Ironwood Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $296.15M | $351.41M | $442.74M | $410.60M | $413.75M | $389.52M |
| Cost of Revenue | - | - | - | - | - | $3.14M |
| Gross Profit | - | - | - | - | - | $386.39M |
| R&D | $95.14M | $111.42M | $116.08M | $44.27M | $70.41M | $88.06M |
| SG&A | $82.26M | $144.27M | $158.31M | $115.99M | $111.13M | $140.00M |
| Total Operating Expenses | $197.65M | $258.29M | $1.39B | $160.26M | $181.49M | $246.58M |
| D&A | $1.10M | $1.20M | $1.20M | $1.40M | $1.50M | $2.30M |
| Operating Income | $98.50M | $93.12M | ($945.43M) | $250.34M | $232.26M | $142.94M |
| Interest Expense | $32.75M | $33.03M | $21.63M | $7.60M | $31.15M | $29.48M |
| Income Tax | $46.01M | $64.32M | $83.49M | $77.36M | ($327.79M) | $2.69M |
| Net Income | $24.02M | $880.0K | ($1.00B) | $175.06M | $528.45M | $106.18M |
| EPS - Basic | $0.15 | $0.01 | ($6.45) | $1.13 | $3.26 | $0.67 |
| EPS - Diluted | $0.15 | $0.01 | ($6.45) | $0.96 | $3.21 | $0.66 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $215.46M | $88.56M | $92.15M | $656.20M | $620.13M | $362.56M |
| Accounts Receivable | $46.74M | $81.89M | $129.12M | $115.46M | $114.04M | $122.35M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.90M | $2.13M | $7.83M | $483.0K | $935.0K | $661.0K |
| Current Assets | $274.18M | $182.37M | $233.29M | $780.63M | $745.23M | $495.84M |
| Total Assets | $396.90M | $350.91M | $471.07M | $1.10B | $1.13B | $559.24M |
| Current Liabilities | $242.22M | $38.85M | $276.10M | $25.52M | $161.70M | $32.17M |
| Long-term Debt | - | - | - | $396.25M | $454.19M | $430.26M |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($261.83M) | ($301.33M) | ($346.30M) | $652.38M | $605.91M | $62.64M |
| Retained Earnings | ($1.67B) | ($1.70B) | ($1.70B) | ($696.38M) | ($937.61M) | ($1.47B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $127.04M | $103.55M | $183.43M | $273.76M | $261.89M | $168.84M |
| Investing Cash Flow | ($34.0K) | ($142.0K) | ($1.03B) | ($136.0K) | ($265.0K) | ($1.84M) |
| Financing Cash Flow | $216.0K | ($106.97M) | $277.16M | ($237.55M) | ($4.55M) | $18.55M |
| CapEx | $34.0K | $142.0K | $273.0K | $136.0K | $265.0K | $1.84M |
| Free Cash Flow | $127.01M | $103.41M | $183.15M | $273.63M | $261.63M | $166.99M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | 99.2% |
| Operating margin | 33.3% | 26.5% | -213.5% | 61.0% | 56.1% | 36.7% |
| EBITDA margin | 33.6% | 26.8% | -213.3% | 61.3% | 56.5% | 37.3% |
| Net margin | 8.1% | 0.3% | -226.4% | 42.6% | 127.7% | 27.3% |
| Free cash flow margin | 42.9% | 29.4% | 41.4% | 66.6% | 63.2% | 42.9% |
| FCF / Net income | 5.29 | 117.51 | -0.18 | 1.56 | 0.50 | 1.57 |
| R&D / Revenue | 32.1% | 31.7% | 26.2% | 10.8% | 17.0% | 22.6% |
| SG&A / Revenue | 27.8% | 41.1% | 35.8% | 28.3% | 26.9% | 35.9% |
| Effective tax rate | 65.7% | 98.7% | - | 30.6% | -163.4% | 2.5% |
| Return on assets | 6.1% | 0.3% | -212.8% | 15.9% | 46.9% | 19.0% |
| Return on equity | -9.2% | -0.3% | 289.4% | 26.8% | 87.2% | 169.5% |
| Return on invested capital | - | - | - | 16.6% | 21.9% | 28.3% |
| Liquidity | ||||||
| Current ratio | 1.13 | 4.69 | 0.84 | 30.58 | 4.61 | 15.41 |
| Quick ratio | 1.13 | 4.69 | 0.84 | 30.58 | 4.61 | 15.41 |
| Cash ratio | 0.89 | 2.28 | 0.33 | 25.71 | 3.84 | 11.27 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.61 | 0.75 | 6.87 |
| Debt / Assets | - | - | - | 0.36 | 0.40 | 0.77 |
| Debt / EBITDA | - | - | - | 1.57 | 1.94 | 2.96 |
| Interest coverage | 3.0x | 2.8x | -43.7x | 32.9x | 7.5x | 4.8x |
| Equity multiplier | -1.52 | -1.16 | -1.36 | 1.69 | 1.86 | 8.93 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.75 | 1.00 | 0.94 | 0.37 | 0.37 | 0.70 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 58d | 85d | 106d | 103d | 101d | 115d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | 77d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 22.5x | 443.0x | - | 12.9x | 3.6x | 17.3x |
| P / B | - | - | - | 3.5x | 3.2x | 29.2x |
| P / S | 1.9x | 2.0x | 4.0x | 5.6x | 4.6x | 4.7x |
| EV / EBITDA | 3.4x | 6.6x | - | 8.1x | 7.5x | 13.1x |
| Growth | ||||||
| Revenue growth (YoY) | -15.7% | -20.6% | 7.8% | -0.8% | 6.2% | -9.1% |
| Revenue CAGR (3y) | -10.3% | -5.3% | 4.4% | -1.4% | 14.7% | 9.3% |
| Revenue CAGR (5y) | -5.3% | -3.9% | 10.1% | 6.6% | 8.6% | 21.1% |
| Gross profit growth (YoY) | - | - | - | - | - | -4.5% |
| Operating income growth (YoY) | 5.8% | - | - | 7.8% | 62.5% | 19.0% |
| Net income growth (YoY) | 2629.2% | - | - | -66.9% | 397.7% | 393.7% |
| EPS growth (YoY) | 1400.0% | - | - | -70.1% | 386.4% | 371.4% |
| EPS CAGR (3y) | -46.1% | -85.4% | - | 90.0% | - | - |
| EPS CAGR (5y) | -25.6% | -41.0% | - | - | - | - |
| FCF growth (YoY) | 22.8% | -43.5% | -33.1% | 4.6% | 56.7% | 4622.7% |
| FCF CAGR (5y) | -5.3% | 96.4% | - | - | - | - |
| Book value growth (YoY) | 13.1% | 13.0% | - | 7.7% | 867.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$880.95M totalCollaborative Arrangements$296.15M · 33.6%
Collaborative Arrangement Collaboration And License Agreements$292.36M · 33.2%
Collaborative Arrangements Linzess$289.32M · 32.8%
Royalty$3.04M · 0.3%
Collaborative Arrangement Other Agreements$87.0K · 0.0%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IRONWOOD PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.